This inventor holds 2 USPTO granted patents. Top assignee: Coave Therapeutics. Active years: 2022-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2026
Title: Philippe Moullier: Innovator in Gene Therapy
Introduction
Philippe Moullier is a prominent inventor based in San Sebastian, Spain. He has made significant contributions to the field of gene therapy, particularly in the development of modified adeno-associated virus vectors. His work aims to advance the treatment of central nervous system diseases.
Latest Patents
Moullier holds a patent for "Modified adeno-associated virus vectors and delivery thereof into the central nervous system." This invention relates to modified adeno-associated virus (AAV) vectors designed for transducing cells in the central nervous system (CNS) of a subject. The modified AAV vectors include at least one surface-bound saccharide and are intended for direct administration to the CNS, excluding intracerebroventricular delivery.
Career Highlights
Philippe Moullier is associated with Coave Therapeutics, a company focused on innovative gene therapies. His expertise in the field has positioned him as a key figure in advancing therapeutic options for CNS diseases.
Collaborations
Moullier collaborates with notable professionals in the field, including Willem F Broekaert, enhancing the impact of his research and innovations.
Conclusion
Philippe Moullier's contributions to gene therapy through his patented innovations are paving the way for new treatments in the field of central nervous system diseases. His work exemplifies the potential of modified AAV vectors in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile